The End Of Small Molecule Drugs? Potential Implications Of US Price ‘Negotiation’
Executive Summary
The drug pricing provisions in the Build Back Better bill include a number of exemptions and protections – each of which could have interesting consequences for pharmaceutical development.
You may also be interested in...
US Pharmas Display Defensive Mettle But Headwinds Mount
US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.
Pharma Braces For Potential Landmark Moment For US Drug Price Controls
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.
No More Generics? Implications Of The US Pricing Bill
Lilly’s view of the impact of the pending US drug pricing reform legislation is that it will require rethinking of all its small molecule development programs. That may sound extreme, but it is a logical response to the incentives in the bill. Does that mean the end of the generic drug era?